US 12,331,024 B2
Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors
Adam Galan, Alameda, CA (US); Wendy Luo, Palo Alto, CA (US); and Ritu Lal, Palo Alto, CA (US)
Assigned to GEN1E LIFESCIENCES INC., Palo Alto, CA (US)
Filed by GEN1E LIFESCIENCES INC., Palo Alto, CA (US)
Filed on Mar. 27, 2024, as Appl. No. 18/618,110.
Application 18/618,110 is a continuation of application No. 18/061,610, filed on Dec. 5, 2022, granted, now 11,976,049.
Application 18/061,610 is a continuation of application No. 17/700,168, filed on Mar. 21, 2022, granted, now 11,555,020, issued on Jan. 17, 2023.
Claims priority of provisional application 63/164,664, filed on Mar. 23, 2021.
Prior Publication US 2024/0228447 A1, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 265/32 (2006.01); A61P 35/00 (2006.01); C07D 295/135 (2006.01)
CPC C07D 265/32 (2013.01) [A61P 35/00 (2018.01); C07D 295/135 (2013.01)] 32 Claims
 
1. A compound having the structure of Formula (6):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein,
R1 is selected from C1-4 alkanediyl, C1-4 heteroalkanediyl, substituted C1-4 alkanediyl, and substituted C1-4 heteroalkanediyl;
R2 is a substituted heterocycloalkyl moiety selected from a bicyclic substituted C5-12 heterocycloalkyl ring, a substituted C5 heterocycloalkyl, and a substituted C7 heterocycloalkyl, wherein,
the substituted heterocycloalkyl moiety comprises the heteroatomic groups N and O; and
R2 is bonded to R1 through a nitrogen heteroatom of the substituted heterocycloalkyl moiety;
R3 is selected from —C(═O)— and —SO2—;
R4 is —N(R5)2 wherein each R5 is independently selected from hydrogen and C1-4 alkyl; and
each substituent is independently selected from —OH, ═O, —NH2, —NO2, C1-6 alkyl, C3-6 cycloalkyl, C6 aryl, C1-6 heteroalkyl, C1-6 heterocycloalkyl, and C5-6 heteroaryl.